Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of IMR-687 in adults with sickle cell disease
NL-OMON55249Phase 2Completed
- Sponsor
- Imara Therapeutics
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tovinontrine in sickle cell disease (SCD) (3 arms), sponsored by Imara Therapeutics. Primary endpoints: Fetal hemoglobin response and Safety and tolerability. Started Sep 2020; status: completed.
02
Drugs
tovinontrine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON55249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55249.